TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02515474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
Study: NCT02844595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cognitive-behavioural smoking cessation treatment
Description: Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cognitive-behavioural smoking cessation treatment and behavioural activation
Description: Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks.
Study: NCT06094465

Intervention type: OTHER
Intervention: Different phase of the learning curve of RPD
Description: Different phases of the learning curve of RPD (learning phase or proficiency phase)

Intervention type: OTHER
Intervention: Different phase of the learning curve of RPD
Description: Different phases of the learning curve of RPD (learning phase or proficiency phase)
Study: NCT01940848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STW5 (Iberogast, BAY98-7411)
Description: Applied orally over 28 days, 20 drops STW 5 three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied orally over 28 days, 20 drops placebo three times daily
Study: NCT00405769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: red yeast rice
Description: 600 mg 3 caps bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 caps bid
Study: NCT03601676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integration of electronic clinical decision support
Description: Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
Study: NCT03612219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablet
Description: Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
Study: NCT04287348

Intervention type: DRUG
Group type: OTHER
Intervention: Brolucizumab 6 mg solution for intravitreal injection
Description: All consenting, enrolled patients (irrespectively of maximum recurrence-free interval under aflibercept pretreatment) will receive an intravitreal injection of brolucizumab 6 mg at baseline (week 0), at week 4 and each of the following treat and extend visits. At each visit all patients will undergo an OCT assessment. For all patients extension of treatment intervals is only possible 2-week-stepwise, e.g. 4, 6, 8 weeks etc.
Study: NCT01610518

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat beta-glucan
Description: 4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat beta-glucan
Description: 4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat beta-glucan
Description: 4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat beta-glucan
Description: 4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
Study: NCT01369433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib + paclitaxel
Description: Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib + temsirolimus
Description: Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (AV-951)
Description: Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib + capecitabine
Description: Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivo
Description: Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
Study: NCT03170310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
Study: NCT00822471

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Self-Management Education
Description: DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor.
Study: NCT01981083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg albumin-based protein supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Renal-specific oral supplement
Study: NCT02347618

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative SBRT
Description: This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
Study: NCT00487188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90 mg subcutaneous injection twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral treatment (HAART)
Description: An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Highly active antiretroviral treatment (HAART)
Description: An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
Study: NCT04561791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered Capsule Endomicroscopy
Description: Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
Study: NCT04160065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFx-Hu2.0
Description: The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses.
Study: NCT04230603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging
Description: Photos were taken with the hyperspectral camera of the human tissue
Study: NCT02759640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241
Description: HS-10241 is administered orally starting at 100 mg/day.
Study: NCT03776279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
Study: NCT00453687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: investigational drug
Study: NCT01299584

Intervention type: DRUG
Intervention: Remifentanil
Description: Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT00896831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ornithine-L-aspartate
Description: L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: 5 g (1 sachet) three times per day for 60 days
Study: NCT04000113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: low level laser emission on specific acupuncture points

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser
Study: NCT01277029

Intervention type: OTHER
Intervention: No drug
Description: Psychopathology, personality traits of patients with lower urinary tract symptoms
Study: NCT02531685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% Sodium Chloride injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% Sodium Chloride injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% Sodium Chloride injection.
Study: NCT04230603

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lactate acid measurement
Description: At the marked regions of the specimen, a lactate acid measurement was performed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pathological examination
Description: At the marked regions of the specimen, the pathological examination was performed.
Study: NCT02764047

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: L. acidophilus 10⁹, B. lactis 10⁹
Study: NCT02531685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% Sodium Chloride injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% Sodium Chloride injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Description: LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.
Study: NCT01757132

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Miniature Telescope
Description: Device - Implantable Miniature Telescope
Study: NCT03076463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GRAPOM
Description: The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
Study: NCT00381212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
Study: NCT02764047

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: L. acidophilus 10⁹, B. lactis 10⁹
Study: NCT00758888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic Blocking
Description: Place the blocks under the pelvis for 2 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trochanter Belt
Description: Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blocking Sham
Description: Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
Study: NCT00512434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis
Description: Nail or external fixator Intervention 'Osteosynthesis'

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Description: Nail or external fixator Intervention 'Osteosynthesis'
Study: NCT01903226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity training
Study: NCT00958841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pasireotide LAR
Description: Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
Study: NCT01125514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Description: Aliskiren 150 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 60 mg
Description: Furosemide 60 mg commercially-available tablets
Study: NCT03019380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: removing cerumen from external ear (Wondertip)
Description: The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
Study: NCT00930618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMN
Description: Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
Study: NCT02693067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rose bengal disodium
Description: Percutaneous intralesional injection to NET tumor
Study: NCT01125514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 60 mg
Description: Furosemide 60 mg commercially-available tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 60 mg
Description: Furosemide 60 mg commercially-available tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Matching placebo for aliskiren 150 mg and 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Matching placebo for aliskiren 150 mg and 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Matching placebo for aliskiren 150 mg and 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg tablet
Study: NCT03325491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.
Study: NCT00858364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Administered subcutaneously once every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously once every 3 weeks
Study: NCT01729442

Intervention type: OTHER
Group type: OTHER
Intervention: Shear-wave ultrasound elastography (SWUE)

Intervention type: OTHER
Group type: OTHER
Intervention: Shear-wave ultrasound elastography (SWUE)

Intervention type: OTHER
Group type: OTHER
Intervention: Shear-wave ultrasound elastography (SWUE)